Patents by Inventor Andrej JANCARIK

Andrej JANCARIK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
    Patent number: 11932664
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: March 19, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Prodrugs of glutamine analogs
    Patent number: 11926640
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: March 12, 2024
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Prodrugs of hydroxamate-based GCPII inhibitors
    Patent number: 11866394
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 9, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Methods for cancer and immunotherapy using prodrugs of glutamine analogs
    Patent number: 11759444
    Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: September 19, 2023
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Jonathan Powell, Lukas Tenora, Pavel Majer, Andrej Jancarik, Robert Leone, Judson Englert
  • Mebendazole prodrugs with enhanced solubility and oral bioavailability
    Patent number: 11712435
    Abstract: Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: August 1, 2023
    Assignees: THE JOHNS HOPKINS UNIVERSITY, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Gregory Riggins, Pavel Majer, Tomas Tichy, Jan Vavra, Andrej Jancarik, Lukas Tenora
  • PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR
    Publication number: 20230115651
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA
    Type: Application
    Filed: May 9, 2022
    Publication date: April 13, 2023
    Inventors: BARBARA SLUSHER, RANA RAIS, MARCELA KRECMEROVA, TOMAS TICHY, PAVEL MAJER, ANDREJ JANCARIK
  • Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
    Patent number: 11325931
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: May 10, 2022
    Assignees: The Johns Hopkins University, Inst of Organic Chem. and Biochemistry AS CR V.V.I
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS
    Publication number: 20210355079
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 18, 2021
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Prodrug compositions and utility of hydroxamate-based GCPII inhibitors
    Patent number: 11059775
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 13, 2021
    Assignees: The Johns Hopkins University, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY
    Publication number: 20210205271
    Abstract: Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.
    Type: Application
    Filed: February 8, 2019
    Publication date: July 8, 2021
    Inventors: Barbara Slusher, Rana Rais, Gregory Riggins, Pavel Majer, Tomas Tichy, Jan Vavra, Andrej Jancarik
  • PRODRUGS OF GLUTAMINE ANALOGS
    Publication number: 20210206787
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set firth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 8, 2021
    Inventors: Barbara SLUSHER, Rana RAIS, Lukas TENORA, Pavel MAJER, Andrej JANCARIK
  • Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs
    Publication number: 20210145779
    Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Application
    Filed: November 23, 2020
    Publication date: May 20, 2021
    Inventors: Barbara SLUSHER, Jonathan Powell, Lukas Tenora, Pavel Majer, Andrej Jancarik, Robert Leone, Judson Englert
  • Prodrugs of glutamine analogs
    Patent number: 10954257
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: March 23, 2021
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR
    Publication number: 20200399298
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA
    Type: Application
    Filed: January 24, 2020
    Publication date: December 24, 2020
    Inventors: BARBARA SLUSHER, RANA RAIS, MARCELA KRECMEROVA, TOMAS TICHY, PAVEL MAJER, ANDREJ JANCARIK
  • Prodrugs of glutamine analogs
    Patent number: 10738066
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: August 11, 2020
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
    Patent number: 10544176
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: January 28, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS
    Publication number: 20190352255
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Application
    Filed: November 20, 2017
    Publication date: November 21, 2019
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • PRODRUGS OF GLUTAMINE ANALOGS
    Publication number: 20190315783
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • PRODRUGS OF GLUTAMINE ANALOGS
    Publication number: 20190315784
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Prodrugs of glutamine analogs
    Patent number: 10336778
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: July 2, 2019
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik